Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

skip to main content

Payer Advocacy for 2020 Updates to Asthma Management

The 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Expert Panel Working Group recommend the use of inhaled corticosteroid/formoterol combination inhalers. To encourage optimal patient care and reflect this standard of practice, the AAAAI has contacted more than 60 commercial, Medicare Advantage and Medicaid plans to request that they classify inhaled corticosteroid/formoterol combination inhalers as preferred in their prescription drug formularies. Read the letter.